BrightSpring Price Targets Raised to $46 and $55 on Generics Momentum
TD Cowen lifted BrightSpring’s price target to $46 from $42 on January 27, citing strong specialty generics trends as the main driver of Q4 momentum. BMO Capital and BTIG subsequently raised targets to $46 and $55, respectively, highlighting the firm’s competitive pharmaceutical ties and consistent Healthcare IT performance.
1. Analyst Upgrades Summary
Between January 23 and February 2, BrightSpring saw three investment firms raise their price targets: TD Cowen to $46 from $42, BMO Capital to $46 from $40, and BTIG to $55 from $50. All maintained Buy or Outperform ratings based on perceived growth potential.
2. Specialty Generics Momentum
TD Cowen highlighted strong specialty generics trends fueling Q4 momentum, while BMO Capital emphasized BrightSpring’s competitive position and solid pharmaceutical partnerships driving its specialty division growth.
3. Segment Operations and Outlook
BTIG cited BrightSpring’s consistent operational performance through market cycles and its Healthcare IT and Digital Health segments as key factors supporting the elevated target. The company operates Pharmacy Solutions and Provider Services, seeking to leverage integrated healthcare delivery.